Routine perioperative chemotherapy instillation with initial bladder tumor resection: A reconsideration of economic benefits

Cancer

Volumn 115, Issue 5, 2009, Pages 997-1004

  Rao, Pravin K ^a   Stephen Jones, J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Drug therapy; Economics; Neoplasms; Perioperative care; Urinary bladder

Indexed keywords

EPIRUBICIN; MITOMYCIN C; PIRARUBICIN; THIOTEPA;

AMBULATORY SURGERY; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; DRUG COST; HEALTH CARE COST; HOSPITAL CARE; HUMAN; OUTPATIENT CARE; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; REIMBURSEMENT; SYSTEMATIC REVIEW; TRANSURETHRAL RESECTION; TUMOR RECURRENCE;

ADMINISTRATION, INTRAVESICAL; AMBULATORY CARE; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; META-ANALYSIS AS TOPIC; NEOPLASM RECURRENCE, LOCAL; PERIOPERATIVE CARE; URINARY BLADDER NEOPLASMS;

EID: 61549091501     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24104     Document Type: Article

References (32)

1. Soloway MS, Martino C. Prophylaxis of bladder tumor implantation. Intravesical and systemic chemotherapy. Urology. 1976;7:29-34.
2. Soloway MS, Masters S. Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer. 1980; 46:1158-1163.
3. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta Tl bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004; 171 (6 pt 1):2186-2190, quiz 2435.
4. Weldon TE, Soloway MS. Susceptibility of urothelium to neoplastic cellular implantation. Urology. 1975;5:824-827.
5. Sobin LH, Wittekind C, eds. TNM Classification of Malignant Tumors, 6th ed. New York, NY: John Wiley & Sons; 2002.
6. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178:2314-2330.
7. Lotan Y, Roehrborn CG. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the follow-up of patients with transitional cell carcinoma of the bladder: a decision analytical approach. J Urol. 2002;167:75-79.
8. Berrum-Svennung I, Granfors T, Jahnson S, Boman H, Holmang S. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol. 2008;179:101-105; discussion 105-106.
9. Tolley DA, Parmar MK, Grigor KM, et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol. 1996;155:1233-1238.
10. Ali-el-Dein B, Nabeeh A, el-Baz M, Shamaa S, Ashamallah A. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder rumours: a prospective, randomized controlled study. Br J Urol. 1997;79:731-735.
11. Bouffioux C, Kurth KH, Bono A, et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol. 1995;153(3 pt 2):934-941.
12. Oosterlinck W, Solsona E, Akaza H, et al. Low-grade Ta (noninvasive) urothelial carcinoma of the bladder. Urology. 2005;66(6 suppl 1):75-89.
13. Donar SM, North A, Dalbagni G, Herr HW. Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm. J Urol. 2004;171(2 pt 1):636-639.
14. Soloway MS, Bruck DS, Kim SS. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol. 2003;170(2 pt 1):438-441.
15. Okamura K, Ono Y, Kinukawa T, et al. Randomized study of single early instillation of (2″R)-4′-O-tetrahydropyranyldoxorubicin for a single superficial bladder carcinoma. Cancer. 2002;94:2363-2368.
16. [No authors listed]. The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer. Br J Urol. 1985;57:680-685.
17. [No authors listed]. The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Medical Research Council Working Party on Urological Cancer, Subgroup on Superficial Bladder Cancer. Br J Urol. 1994;73:632-638.
18. Oosterlinck W, Kurth KH, Schroder F, Bultinck J, Hammond B, Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol. 1993;149:749-752.
19. Rajala P, Kaasinen E, Raitanen M, Liukkonen T, Rintala E. Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study - FinnBladder III long-term results. J Urol. 2002;168:981-985.
20. Rajala P, Liukkonen T, Raitanen M, et al. Transurethral resection with perioperative instilation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study - FinnBladder III. J Urol. 1999;161:1133-1135; discussion 1135-1136.
21. Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Dumonr R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up. J Urol. 1999; 161:1120-1123.
22. Tolley DA, Hargreave TB, Smith PH, et al. Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). BMJ (Clin Res Ed). 1988;296:1759-1761.
23. Brassell SA, Kamat AM. Contemporary intravesical treatment options for urothelial carcinoma of the bladder. J Natl Compr Cane Netw. 2006;4:1027-1036.
24. Shapiro O, Jones K, Wang C, Landas S, Haas GP. Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection. Can J Urol. 2006;13:3317-3320.
25. O'Donnell MA. Practical applications of intravesical chemotherapy and immunotherapy in high-risk patients with superficial bladder cancer. Urol Clin North Am. 2005;32:121-131.
26. Cai T, Nesi G, Tinacci G, et al. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study. J Urol. 2008;180:110-115.
27. Cliff AM, Romaniuk CS, Parr NJ. Perivesical inflammation after early mitomycin C instillation. BJU Int. 2000;85:556-557.
28. Nieuwenhuijzen JA, Bex A, Horenblas S. Unusual complication after immediate postoperative intravesical mitomycin C instillation. Eur Urol. 2003;43:711-712.
29. Oddens JR, van der Meijden AP, Sylvester R. One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe? Eur Urol. 2004;46:336-338.
30. Doherty AP, Trendell-Smith N, Stirling R, Rogers H, Bellringer J. Perivesical fat necrosis after adjuvant intravesical chemotherapy. BJU Int. 1999;83:420-423.
31. Koya MP, Simon MA, Soloway MS. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol. 2006;175:2004-2010.
32. Liu CC, Chou YH, Huang CH, Tsai KB. Bladder wall calcification after intravesical chemotherapy with mitomycin C - a case report. Kaohsiung J Med Sci. 2001; 17:274-277.